Key Drivers
- Strong Margins
- Cash Generation
- Liquidity Pressure
AIAI Summary
AZN is still a high-quality pharma franchise, but the stock is now a “prove-it” story where continued upside depends on oncology-led growth and pipeline execution offsetting Wainua setbacks, legal overhangs, and a stretched valuation, so investors should wait for cleaner cash conversion and sustained revenue acceleration before paying for further rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Cash Generation
- •Liquidity Pressure
AZN remains highly profitable with strong cash generation and efficient capital use, but near-term liquidity, leverage, and a full valuation temper the investment case.
Price Behavior
Key Price Behavior Insights:
- •Lower highs/lows
- •Failed rebound
- •Support watch
AZN's last month is still in a short-term downtrend, with lower highs/lows and a failed bounce from the 2026-08-04 low, so a break back above $161–$163 is needed to ease pressure.
Brief rebound into 2026-08-10 stalled below resistance
Sentiment & News
Key News Insights:
- •Earnings beat
- •Legal overhang
- •Institutional buying
AstraZeneca beat Q2 expectations on stronger oncology and rare-disease demand, reaffirmed its outlook and 2030 revenue लक्ष्य, but ongoing legal probes and prior share कमजोरी kept sentiment mixed despite steady institutional buying.
The news is moderately positive for fundamentals, but recurring legal headlines and market volatility may cap near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings